\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes CybersecurityThe evaluation of proposals submitted under call DIGITAL-ECCC-2024-DEPLOY-CYBER-06 (submission deadline 26 March 2024) have been completed. The results of the evaluation are as follows:
DIGITAL-2024-DEPLOY-CYBER-06-ENABLINGTECH
DIGITAL-ECCC-2024-DEPLOY-CYBER-06-STRENGTHENCRA
DIGITAL-ECCC-2024-DEPLOY-CYBER-06-COMPLIANCECRA
DIGITAL-ECCC-2024-DEPLOY-CYBER-06-PQCINDUSTRY
DIGITAL-ECCC-2024-DEPLOY-CYBER-06-STANDARDPQC
DIGITAL-ECCC-2024-DEPLOY-CYBER-06-TRANSITIONEUPQC
The applicants have recently been informed about the evaluation results for their proposals.
It is expected that the first grant agreements will be signed by 23 December 2024.
Please note that the number of proposals that can finally be funded will depend on the finally available budget and the formal selection by the Commission.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Health Culture and society Security
In the context of simplification, the Commission has introduced the following substantial changes in the Standard Application Form (Version 5.0) for Horizon Europe Research & Innovation Actions (RIA) and Innovation Actions (IA) and Coordination and Support Actions (CSA): Simplified section 2.1 'Project's pathways towards impac... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
